Lipocine Inc Q3 revenue surges on license and royalty income

Overview

• US specialty pharma firm's Q3 revenue rose sharply year-over-year, driven by license and royalty income

• Net loss for Q3 narrowed compared to prior year

• Lower R&D expenses reflect reduced clinical study costs

Outlook

• Company has begun Phase 3 BLOOM study for LPCN 1154 in postpartum depression

• Company may initiate Phase 2 study of LPCN 2201 for major depressive disorder, pending resources

Result Drivers

• LICENSE AND ROYALTY INCOME - Q3 revenue driven by license and collaboration revenue and royalties from TLANDO sales

• LOWER CLINICAL COSTS - Reduced R&D expenses due to lower costs for LPCN 2401 and LPCN 1154 studies

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Lipocine Inc is $5.00, about 247.2% above its November 4 closing price of $1.44

Reuters Recommended Reads

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

• Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

• Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)